- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01894087
Safety & Prevention Outcomes Study (SPOS)
A Brief Prescription Opioid Overdose Intervention in an Emergency Department
Unintentional poisoning is a developing public health problem in the U.S. Unintentional poisoning (or "overdose") deaths increased 157% among adults between 1999 and 2008. There were ~700,000 emergency department (ED) visits due to overdoses in 2007. Medication-related overdoses, particularly prescription opioid overdoses, have accounted for much of this increase. There have been parallel increases in sales of opioids (with a 6 fold increase between 1997 and 2007), as well as both medical and non-medical use of prescription opioids. Prescription opioids are now among the most common of drugs used non-medically in the U.S.
The specific aims of this project are to: 1) Develop an ED-based tailored brief prescription opioid overdose prevention intervention. We will examine therapeutic alliance, perceived satisfaction, and perceived utility of the intervention; 2) Examine intervention effects on precursors of overdose risk behavioral change immediately post-intervention. We will compare intervention and control participants on knowledge, self-efficacy, readiness to change, and behavioral intentions regarding overdose risk behavior; and 3) Examine intervention effects on overdose risk behaviors six months post-intervention. We will compare intervention and control participants on: 1) use of high dose/quantity of opioids; 2) using opioids in combinations with certain psychoactive substances (i.e., alcohol, heroin, cocaine, and sedatives); and, 3) route of administration.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health System Emergency Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients 18-60 presenting to the ED for medical care
- ability to provide informed consent
- Additional criteria for intervention: past extramedical opioid use
Exclusion Criteria:
- patients who do not understand English
- prisoners
- patients classified by medical staff as a "Level 1" trauma (e.g., in need of immediate lifesaving procedures)
- patients deemed unable to provide informed consent
- patients treated in the ED for suicide attempt or sexual assault
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Therapist-led brief intervention (TBI) - Cohort 1
Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist.
The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors.
This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a "change plan" for each participant.
|
|
|
No Intervention: Enhanced usual care - Cohort 1
|
|
|
Active Comparator: Therapist-led brief intervention (TBI) - Cohort 2
Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist.
The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors.
This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a "change plan" for each participant.
|
|
|
No Intervention: Enhanced usual care - Cohort 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overdose Risk Behavior
Time Frame: 6 months post-baseline
|
This scale is a total sum of 9 items assessing participant's self-report of engaging in behavior that increases risk for overdose.
Higher scores indicate greater risk for overdose.
The range for this measure is 0 to 28 in one assessment.
Results reported here as group means are for the change in sum score between baseline and follow-up, which had a possible range of -28 to 28, with lower values indicating greater decreases in overdose risk behavior.
|
6 months post-baseline
|
|
Overdose Knowledge
Time Frame: 6 months post-baseline
|
Overdose symptom knowledge was assessed using an inventory of 5 true symptoms and 2 false symptoms of overdose, and the total score created as the sum of correct answers, with a range of 0 to 7. Due to the skewed distribution, this total score was standardized by subtracting the observed responses from the overall sample mean, and then dividing by the standard deviation.
This resulted in a range of -5.4 to 2.6 in this sample at the 6 month follow-up, with higher numbers indicating greater overdose symptom knowledge.
Also reported here are change scores generated by subtracting the standardized sum score at 6 months from the baseline standardized sum score, which had a range of -3.0 to 6.4 in this sample.
Thus, higher numbers in this "change" variable indicated greater improvements in overdose symptom knowledge.
Negative numbers would represent a decrease in symptom knowledge.
|
6 months post-baseline
|
|
Behavioral Intentions
Time Frame: 6 months post-baseline
|
Behavioral intentions were assessed with three items that measured participant's intention to use overdose risk reduction strategies.
The three strategies were (1) using opioids as prescribed, (2) reducing or avoiding use of alcohol, drugs, or non-prescribed medications, and (3) avoiding combining substances.
Each item was assessed on a scale of 1 to 10, with higher numbers indicating greater intention to avoid overdose risk.
|
6 months post-baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Substance Use - Current Opioid Misuse Measure
Time Frame: 6 months post-baseline
|
This measure contained 8 items from the Current Opioid Misuse Measure.
Items were assessed on a scale of "never (0)," "rarely (1)," "sometimes (3)," "often (4)," and "very often (5)."
A sum score took a range of 0 to 40, with higher numbers indicating more non-medical opioid use.
For group means reported here, change scores were calculated by subtracting the baseline level of this measure from the level at 6 months follow-up.
This change score has a possible range of -40 to 40, with lower values indicating greater decreases in non-medical opioid use.
|
6 months post-baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amy Bohnert, Ph.D., University of Michigan
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R49CE002099 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-Related Disorders
-
Bicycle HealthTerminatedOpioid Use Disorder | Opioid Dependence | Opioid Use | Opioid Abuse | Opioid MisuseUnited States
-
Baylor College of MedicineChandrakantanWithdrawnOpioid Dependence | Opioid Use | Opioid Abuse, Unspecified
-
University of ArkansasNational Institute on Drug Abuse (NIDA)CompletedOpioid Dependence | Opioid Withdrawal | Opioid DetoxificationUnited States
-
MindLight, LLCHarvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaboratorsCompletedOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
Indiana UniversityNational Institute on Drug Abuse (NIDA); Indiana Clinical and Translational...Not yet recruitingOpioid Use Disorder | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid Withdrawal | Intrauterine Exposure
-
University of MinnesotaRecruitingOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
University of PennsylvaniaCompletedSurgery | Opioid Use | Opioid Misuse | Prescription Opioid MisuseUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Columbia University; Weill Medical College... and other collaboratorsEnrolling by invitationOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
Clinical Trials on TBI - Cohort 1
-
Janssen Research & Development, LLCCompletedRelapsed or Refractory Hodgkin LymphomaFrance, Germany
-
AstraZenecaCompletedCOVID-19, SARS-CoV-2Japan
-
XOMA (US) LLCCompletedCongenital HyperinsulinismUnited Kingdom, United States
-
Janssen Research & Development, LLCPharmacyclics LLC.CompletedCD20-positive B-cell Non-Hodgkin LymphomaUnited States, France
-
University of Alabama at BirminghamTerminatedOvarian Cancer | Resistant BRCA Wild-Type Ovarian CancerUnited States
-
Kangabio AUSTRALIA LTD PTYActive, not recruiting
-
University of PennsylvaniaChildren's Hospital of PhiladelphiaActive, not recruiting
-
PfizerCompleted
-
Akesobio Australia Pty LtdCompletedAtopic DermatitisNew Zealand, Australia